Tags

Type your tag names separated by a space and hit enter

Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.
Eur J Haematol. 2006 Jan; 76(1):83-5.EJ

Abstract

Light chain deposition disease (LCDD) is a multisystemic disorder seen in the setting of plasma cell dyscrasias. The histological characteristic of this disorder is the deposition of a homogeneous, granular, slightly eosinophilic and non-Congophilic material that shows immunostaining for monoclonal light chains (kappa or gamma), while in primary amyloidosis (AL) the proteinaceous substance is fibrillar and Congo red positive. In contrast with AL, the light chain in LCDD is usually of the kappa-type. Renal involvement, resulting in nephrotic syndrome, is usually the prominent feature of LCDD. Patients with this disease may also have heart, liver or other organ involvement, mimicking the picture of primary systemic amyloidosis. However, liver failure has rarely been described in patients with LCDD. A patient with myeloma-associated LCDD who developed rapidly progressive liver kappa light chain deposition with fatal outcome after undergoing the first cycle of vincristine/doxorubicin/dexamethasone chemotherapy is reported.

Authors+Show Affiliations

Department of Oncology, Instituto de Enfermedades Neoplásicas, Surquillo, Perú.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16343276

Citation

Samanez, César, et al. "Development of Rapidly Progressive Liver Light Chain Deposition Under VAD Chemotherapy in Multiple Myeloma." European Journal of Haematology, vol. 76, no. 1, 2006, pp. 83-5.
Samanez C, Domingo A, Cibeira MT, et al. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. Eur J Haematol. 2006;76(1):83-5.
Samanez, C., Domingo, A., Cibeira, M. T., Miquel, R., Soler, M., & Bladé, J. (2006). Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. European Journal of Haematology, 76(1), 83-5.
Samanez C, et al. Development of Rapidly Progressive Liver Light Chain Deposition Under VAD Chemotherapy in Multiple Myeloma. Eur J Haematol. 2006;76(1):83-5. PubMed PMID: 16343276.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. AU - Samanez,César, AU - Domingo,Abel, AU - Cibeira,M Teresa, AU - Miquel,Rosa, AU - Soler,Manel, AU - Bladé,Joan, PY - 2005/12/14/pubmed PY - 2006/3/2/medline PY - 2005/12/14/entrez SP - 83 EP - 5 JF - European journal of haematology JO - Eur. J. Haematol. VL - 76 IS - 1 N2 - Light chain deposition disease (LCDD) is a multisystemic disorder seen in the setting of plasma cell dyscrasias. The histological characteristic of this disorder is the deposition of a homogeneous, granular, slightly eosinophilic and non-Congophilic material that shows immunostaining for monoclonal light chains (kappa or gamma), while in primary amyloidosis (AL) the proteinaceous substance is fibrillar and Congo red positive. In contrast with AL, the light chain in LCDD is usually of the kappa-type. Renal involvement, resulting in nephrotic syndrome, is usually the prominent feature of LCDD. Patients with this disease may also have heart, liver or other organ involvement, mimicking the picture of primary systemic amyloidosis. However, liver failure has rarely been described in patients with LCDD. A patient with myeloma-associated LCDD who developed rapidly progressive liver kappa light chain deposition with fatal outcome after undergoing the first cycle of vincristine/doxorubicin/dexamethasone chemotherapy is reported. SN - 0902-4441 UR - https://www.unboundmedicine.com/medline/citation/16343276/Development_of_rapidly_progressive_liver_light_chain_deposition_under_VAD_chemotherapy_in_multiple_myeloma_ L2 - https://doi.org/10.1111/j.1600-0609.2005.00561.x DB - PRIME DP - Unbound Medicine ER -